Use of chlorine Guanabenz derivatives for treating prion-based diseases

Abstract

The invention relates to chlorine Guanabenz derivatives for treating prion-based diseases. More specifically, it relates to the use of the molecule of formula (I) wherein R═H or Cl and the phenyl group is at least substituted twice, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating prion-based diseases.

1 . Use of the molecule of formula: 
       
         
           
           
               
               
           
         
         wherein R═H or C1 and the phenyl group is at least substituted twice, or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating prion-based diseases. 
       
     
     
         2 . Use according to  claim 1 , wherein the molecule is of formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating prion-based diseases. 
       
     
     
         3 . Use according to  claim 2 , wherein the molecule is the acetate salt of formula: 
       
         
           
           
               
               
           
         
         for the manufacture of a medicament for treating prion-based diseases. 
       
     
     
         4 . Use according to  claim 1 , wherein the molecule is of formula: 
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt thereof, for the manufacture of a medicament for treating prion-based diseases. 
       
     
     
         5 . Use according to  claim 1 , wherein the prion-based disease is selecting in the group consisting of bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, Gerstmann-Sträussler-Scheinker syndrome, fatal familial insomia, kuru, scrapie, chronic wasting disease, feline spongiform encephalopathy and exotic ungulate encephalopathy. 
     
     
         6 . Use according to  claim 5 , wherein the prion-based disease is selecting in the group consisting of bovine spongiform encephalopathy, Creutzfeldt-Jakob disease, kuru, scrapie.